Paolo Strati, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the clinical implications of cytopenias 30 days or more after axicabtagene ciloleucel therapy in relapsed/refractory large B-cell lymphoma. He emphasizes the need for viral prophylaxis and monitoring of CD4+ cell counts. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.